Idera Pharmaceuticals, Inc. (IDRA)
| Market Cap | 226.10M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -87.24M |
| Shares Out | 35.09M |
| EPS (ttm) | -2.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $5.95 |
| Previous Close | $5.94 |
| Change ($) | 0.01 |
| Change (%) | 0.17% |
| Day's Open | 5.95 |
| Day's Range | 5.69 - 6.00 |
| Day's Volume | 548,417 |
| 52-Week Range | 1.06 - 6.00 |
EXTON, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences.
Idera Pharmaceuticals (IDRA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
EXTON, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement ...
– COO Role is Key to Preparedness for NDA Filing and Commercial Launch – – Clayton Fletcher , Head of Business Development & Strategic Planning , to Retire –
ILLUMINATE-301 Continues on Track and Beyond Melanoma Strategy Advances ILLUMINATE-301 Continues on Track and Beyond Melanoma Strategy Advances
– Protects Method-of-Use in CRC and HNSCC – – Protects Method-of-Use in CRC and HNSCC –
EXTON, Pa., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA) today announced that final data from the ILLUMINATE-204 trial investigating intratumoral t...
Enhanced Financial Flexibility as ILLUMINATE-301 Continues on Track Enhanced Financial Flexibility as ILLUMINATE-301 Continues on Track
EXTON, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with institutional investors provid...
EXTON, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today announced preliminary data from the first 10 patients in the safety cohort of I...
– Overall response rate of 22% – – Disease control rate of 71% – – Median overall survival of 21 months – – Key topline data from ILLUMINATE-301 expected in Q1 2021 –
EXTON, Pa., April 07, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with an institutional investor pro...
– Completed Enrollment in ILLUMINATE-301; Top-Line Overall Response Rate (ORR) Data Expected in Q1 2021 – – Completed Enrollment in ILLUMINATE-301; Top-Line Overall Response Rate (ORR) Data Ex...
Idera (IDRA) closes enrollment in the late-stage ILLUMINATE-301 study, evaluating the combo of tilsotolimod plus Yervoy in patients with anti-PD-1 refractory advanced melanoma.
Overall Response Rate (ORR) Data Anticipated Q1 2021 Overall Response Rate (ORR) Data Anticipated Q1 2021
EXTON, Pa., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today it is entering into an agreement with funds affiliated with an insti...
EXTON, Pa., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today that the U.S. Patent and Trademark Office will issue on November 5, ...
EXTON, Pa., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today the initiation of a phase 2 trial, ILLUMINATE-206 which will evaluate tilsotolimod, ...
EXTON, Pa., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the Baird 2019 Global Healthcare Conference on Wedne...
Idera Pharmaceuticals, Inc. (IDRA) CEO Vincent Milano on Q2 2019 Results - Earnings Call Transcript
Idera (IDRA) delivered earnings and revenue surprises of 7.14% and 1348.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Idera (IDRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
As of late, it has definitely been a great time to be an investor in Idera Pharmaceuticals, Inc. (IDRA).
Idera (IDRA) delivered earnings and revenue surprises of 13.04% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Idera (IDRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About IDRA
Idera Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has collaboration and supply agreement with AbbVie Inc. and Bristo... [Read more...]
| Industry Biotechnology | IPO Date Jan 24, 1996 |
| CEO Vincent Milano | Employees 36 |
| Stock Exchange NASDAQ | Ticker Symbol IDRA |
Financial Performance
In 2019, IDRA's revenue was $1.45 million, an increase of 118.73% compared to the previous year's $662,000. Losses were -$56.52 million, -5.62% less than in 2018.
Analyst Forecasts
According to 6 analysts, the average rating for IDRA stock is "Buy." The 12-month stock price forecast is 7.83, which is an increase of 31.60% from the latest price.